Societal CDMO, Inc. announced the signing of a co-marketing agreement. The agreement is designed to allow the companies to promote each other?s complementary contract development and manufacturing services to their respective customer bases and new business prospects. As part of the agreement, the companies will highlight Benuvia?s specific expertise as a manufacturer of drug substance (API) and Societal?s focus on manufacturing drug product.

While the agreement is not limited to any specific therapeutic indication or modality, the companies will specifically focus on leveraging their unique expertise in the area of psychedelics to address this expanding drug development market. Societal CDMO possesses a broad range of CDMO capabilities spanning formulation development, analytical testing and manufacturing of oral solid dose finished drug products. The company has several decades of experience in manufacturing and handling controlled substances.

In 2023, the company received U.S. Drug Enforcement Agency (DEA) approval to add certain Schedule 1 psychedelic compounds to its controlled substance manufacturing registration, expanding upon the Schedule 2 manufacturing registration it has held with the DEA for over 20 years. This expansion of its controlled substance capabilities has placed the company in a strong position to support customers with the manufacture of high-quality cGMP clinical supplies for the growing number of ongoing and planned clinical trials in the psychedelic drug development area. Benuvia Operations, LLC, is an end-to-end CDMO with vertically integrated pharmaceutical services ranging from drug and formulation development, fully-integrated analytical services and manufacturing of oral liquid and aerosol solutions.

The company excels in producing controlled substances (DEA schedule I-III), with a focus in the areas of cannabinoids and psychedelics. Distinguished by its commercial drug master files referenced in approved pharmaceutical New Drug Applications and as an established global supplier of controlled substances, Benuvia is rapidly expanding its influence in the emerging cannabinoid and psychedelic market. Benuvia?s journey is reaffirming its commitment to innovation and quality in pharmaceutical manufacturing as it embraces innovation and upholds the highest standards of production in serving the evolving needs of the global market.